Genmab stock gains analyst support as Barclays lifts target price

Genmab A/S stock (ISIN DK0010272202) is trading below recent highs but with fresh backing from major banks, after Barclays lifted its price target and the company called an extraordinary general meeting for October 7, 2026, to address board remuneration and shareholder outreach as disclosed on September 8, 2026.TipRanks

Barclays raises target, consensus stays supportive

On September 8, 2026, MarketScreener reported that Barclays raised its price target for Genmab stock to 2,900 Danish kroner from 2,500 Danish kroner, while maintaining an Overweight recommendation. This new target sits clearly above the current consensus, which stands at an average objective of about 2,453.79 Danish kroner, implying that Barclays now expects roughly 18.2 percent more upside than the broader analyst pool at this level.MarketScreener

According to the same overview, the last closing price for Genmab shares on Nasdaq Copenhagen was 2,141.00 Danish kroner as of September 7, 2026, representing a daily decline of 1.11 percent but a year-to-date gain of 5.62 percent.MarketScreener With an average price target of 2,453.79 Danish kroner, the implied upside from this 2,141.00 Danish kroner close is about 14.6 percent, underscoring that analysts still see room for appreciation even after the stock’s advance earlier in the year.MarketScreener

Other banks reaffirm Buy ratings and upside potential

The positive stance from Barclays comes on top of other recent supportive calls. On September 4, 2026, Bank of America Securities analyst Charlie Haywood maintained a Buy rating on Genmab and set a price target of 2,500.00 Danish kroner, with the shares having closed the prior trading session at 2,165.00 Danish kroner.The Globe and Mail At that level, the bank’s target implied a potential upside of roughly 15.5 percent versus the then closing price, signaling confidence in the company’s medium-term earnings path.The Globe and Mail

The same analyst summary shows that Genmab has a one-year high of 2,257.00 Danish kroner and a one-year low of 1,512.00 Danish kroner, meaning that the September 7, 2026 close at 2,141.00 Danish kroner left the stock trading about 5.1 percent below its 12-month peak and roughly 41.7 percent above its 12-month low.The Globe and Mail For investors, this range highlights both the volatility in biotech valuations and the fact that the stock remains closer to its high than its trough, consistent with the strong Buy consensus cited in recent coverage.The Globe and Mail

Extraordinary general meeting adds governance focus

Beyond analyst calls, Genmab has introduced a governance and shareholder-relations angle that matters for long-term holders. On September 8, 2026, the company announced an Extraordinary General Meeting to be held at its Copenhagen headquarters on October 7, 2026, with board remuneration and shareholder outreach among the key agenda items.TipRanks According to the announcement summary, the proposal includes putting a board fee of 600,000 Danish kroner to a shareholder vote, illustrating that compensation levels and investor communication are under active review.Stock Titan

This kind of governance event can influence sentiment even without immediate financial figures. For some institutional investors, clearer board pay structures and a formal discussion of outreach programs are part of assessing execution risk around Genmab’s pipeline and partnerships. While short-term traders focus on price targets and technical levels, long-term shareholders often watch whether the board’s incentives are aligned with sustained value creation.

Recent fundamentals and earnings expectations

Within the current reporting window, analysts are projecting continued growth for Genmab’s top line, reflecting expectations around its antibody portfolio and collaborations. A recent consensus compilation cited by a Korean financial outlet indicates that for fiscal year 2027, revenue is expected to reach about 4,497.0 million dollars, up 20.90 percent from the prior year, with further growth to approximately 5,238.0 million dollars in 2028 and 6,319.0 million dollars in 2029.Maeil Business Newspaper These figures, while forward-looking, underline that the market is currently pricing Genmab as a growth biotech with double-digit annual revenue expansion.

The same consensus suggests that earnings per share may face a dip before rebounding sharply. For 2027, EPS is projected at 1.15 dollars, down 25.04 percent year on year, but then rising to 1.79 dollars in 2028, a 55.06 percent improvement, and reaching 2.81 dollars in 2029, up 57.28 percent.Maeil Business Newspaper For investors, this pattern of near-term margin pressure followed by stronger profitability supports the idea that the recent analyst price targets are built on a multi-year earnings recovery rather than purely short-term moves.

Valuation lens: market capitalization and ADR price

From a market-capitalization perspective, Genmab remains a sizable player in global biotech. As of early September 2026, one global stock overview estimates the company’s market capitalization at 20.65 billion dollars, based on a share price of 33.60 dollars for its American depositary shares.CompaniesMarketCap This places Genmab among the world’s mid-sized large-cap companies and underscores the scale at which its antibody platforms are being valued.

According to Yahoo Finance, Genmab’s ADSs (ticker GMAB) last closed at 33.60 dollars on September 4, 2026, on Nasdaq, a daily decline of 2.35 percent from the prior close. With the ADS representing Genmab’s Copenhagen-listed shares in dollar form, moves on Nasdaq typically mirror the underlying Danish listing while giving US-based investors direct access. At the same time, the CompaniesMarketCap snapshot lists Genmab’s 2026 market capitalization change at negative 0.32 percent so far, suggesting that despite the year-to-date gain on the Copenhagen line, the overall dollar valuation has been broadly flat.CompaniesMarketCap

Risks and counter-factors for Genmab stock

Even with multiple Buy ratings, Genmab stock is not without risks. The expected near-term EPS decline in 2027 compared with the previous year reflects potential pressure from R&D spending, milestone timing, or competitive dynamics in oncology and immunology markets.Maeil Business Newspaper If clinical data or regulatory outcomes diverge from expectations, the projected rebound in EPS for 2028 and 2029 may not materialize as foreseen, which could lead to downward revisions of the current 2,500.00 to 2,900.00 Danish kroner price targets.

Another factor is valuation sensitivity. With the shares trading closer to their one-year high than to their low and consensus pointing to double-digit percentage upside, disappointment in trial results or partnership revenues could trigger sharper price reactions than for a more defensively valued stock.The Globe and Mail Finally, governance outcomes from the October 7, 2026 extraordinary general meeting will be watched closely; if investors judge board remuneration or outreach measures as misaligned with performance, that could weigh on sentiment even if fundamentals remain solid.Stock Titan

Key product and business focus

Genmab’s core business revolves around the research and development of human therapeutic antibodies, targeting cancers, infectious diseases, rheumatoid arthritis and related immune conditions.MarketScreener The company’s strategy has long been to leverage proprietary antibody technologies and then work with larger pharmaceutical partners to bring drugs to market, sharing in royalties and milestone payments. For retail investors, this means that Genmab’s revenue and EPS trajectories are closely tied to the performance of specific antibody programs and the strength of its licensing agreements rather than to a single blockbuster product alone.

Genmab stock on Copenhagen and via ADS

In Copenhagen trading, the reference price for Genmab stock is the Nasdaq Copenhagen close of 2,141.00 Danish kroner as of September 7, 2026, with that level marking a 1.11 percent decline on the day but a 5.62 percent increase since the start of the year.MarketScreener On Nasdaq in the United States, the company’s ADSs closed at 33.60 dollars on September 4, 2026, down 2.35 percent from the prior session.Yahoo Finance Together, these quotes frame Genmab as a biotech name that has appreciated moderately in 2026, is trading near but not at its one-year high of 2,257.00 Danish kroner, and still carries double-digit percentage upside in the eyes of many analysts.The Globe and Mail

More news and analyses on Genmab stock